01:36 , Jun 8, 2018 |  BC Innovations  |  Tools & Techniques

NK cell check-in

Until recently, there’s been scarce overlap between the NK cell field and the world of checkpoint inhibitors, with the former focused on cell therapies to kill tumor cells directly and the latter on relieving immune...
18:33 , Apr 3, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Melanoma, colorectal cancer Mouse studies suggest antibodies against the conserved α3 domain of MICA and MICB could help treat metastatic melanoma and colorectal cancer. In mouse models of metastatic melanoma and colon cancer, a mAb...
13:14 , Mar 30, 2018 |  BC Extra  |  Preclinical News

Targeting stress proteins on cells to help treat cancer

Researchers at the Dana-Farber Cancer Institute identified a mAb that binds to a domain on stress proteins expressed by cancer cells, thereby impeding the cancer from sloughing off the protein to escape natural killer cells....
23:17 , Oct 5, 2017 |  BC Innovations  |  Product R&D

Avidly specific

With its first two programs headed for the clinic next year, AvidBiotics Corp. is seeing the fruits of its move to human therapeutics from food safety and animal health. Using engineered peptides, the company has...
22:57 , Jun 29, 2017 |  BC Innovations  |  Product R&D

Drop the MIC

Two start-ups have joined the wave of companies harnessing NK cell biology to generate new immunotherapies for cancer by focusing on the relatively unexplored ligands for the NK cell receptor NKG2D. Having laid low for...
07:00 , Jul 28, 2016 |  BC Innovations  |  Tools & Techniques

Innate harmony

On the heels of cancer immunotherapy's clinical success, NK cells - a long-known but underappreciated component of the innate immune system - are emerging as the hottest new tool to fight cancer, with the potential...
07:00 , May 20, 2013 |  BioCentury  |  Emerging Company Profile

Galileo: A TALL order

Galileo Research S.r.L's allogeneic stem cell therapy mimics natural killer cells to stimulate tumor cell apoptosis, but does not attack healthy cells. The off-the-shelf therapy could have broader activity against cancer than allogeneic vaccines in...
07:00 , Jul 26, 2010 |  BC Week In Review  |  Clinical News

PsoriasisDX regulatory update

DermaGenoma received CE Mark approval in the EU for its PsoriasisDX Genetic Test for Psoriatic Arthritis (PsA) to identify patients at high risk for developing PsA. The test detects the presence or absence of a...
08:00 , Feb 19, 2009 |  BC Innovations  |  Distillery Therapeutics

Indication: Pulmonary disease

This week in therapeutics Indication Target/ marker/pathway Summary Licensing status Publication and contact information Pulmonary disease ...
07:00 , Aug 21, 2008 |  BC Innovations  |  Cover Story

Stressing Out Over miRNA

Two papers, one published in the Proceedings of the National Academy of Sciences 1 and the other in Nature Immunology,2 identify several microRNAs that play a role in cellular stress triggered by myocardial infarction or...